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Summary
Background Women have a better melanoma prognosis, and fairer skin/hair colour.
The presence of inherited MC1R variants has been associated with a better mela-
noma prognosis, but its interaction with sex is unknown.
Objectives To evaluate the relationship between germline MC1R status and survival,
and determine any association with sex.
Methods This was a cohort study including 1341 patients with melanoma from
the Melanoma Unit of the Hospital Clinic of Barcelona, between January 1996
and April 2018. We examined known sex-related prognosis factors as they relate
to features of melanoma and evaluated the sex-specific role of MC1R in overall
and melanoma-specific survival. Hazard ratios (HRs) were calculated using uni-
variate and multivariate Cox logistic regression.
Results Men showed lower overall survival than women (P < 0001) and the pres-
ence of inherited MC1R variants was not associated with better survival in our
cohort. However, in women the presence of MC1R variants was associated with
better overall survival in the multivariate analysis [HR 057, 95% confidence
interval (CI) 038–085; P = 0006] but not in men [HR 126, 95% CI 089–
179; P = 0185 (P-value for interaction 0004)]. Analysis performed for mela-
noma-specific survival showed the same level of significance.
Conclusions Inherited MC1R variants are associated with improved overall survival in
women with melanoma but not in men. Intrinsic sex-dependent features can mod-
ify the role of specific genes in melanoma prognosis. We believe that survival stud-
ies of patients with melanoma should include analysis by sex and MC1R genotype.
What’s already known about this topic?
• Inherited MC1R variants have been associated with a better melanoma prognosis,
but their interaction with sex is unknown.
What does this study add?
• MC1R variants are related to better overall survival and melanoma-specific survival
in women but not in men.
What is the translational message?
• These differences between the sexes could imply future changes in melanoma fol-
low-up and treatment strategies.
• This provides a basis for understanding the interaction between sex-related genes
and germline variants in cancer.
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Melanoma is the most aggressive of the common skin malig-
nancies and is responsible for 75% of deaths from skin can-
cer.1 The American Joint Committee of Cancer staging system
gives a clear prognostic value for patients with melanoma but
cannot explain individual differences in survival.2
Femaleness has been demonstrated to be an independent,
favourable prognostic factor in cutaneous malignant melanoma
across nearly all tumour stages, including thin invasive
tumours and advanced melanomas.3–7 Furthermore, males
exhibit worse prognostic features, as they are more likely to
have thick or ulcerated melanomas, and melanoma located on
the trunk.7–9 Moreover, recent data highlight differences in
body mass index and interferon regulation between men and
women that may differently affect antitumour responses to
immunotherapy.10,11
Women have a higher prevalence of lighter hair colour and
fairer skin than men.12,13 The interaction between sex and
genetic variants associated with tanning facility has been
reported recently.14
MC1R is a highly polymorphic gene in the white population
and one of the most important regulator genes in human skin
and hair pigmentation.15–17 MC1R variants have been classified
as ‘r’ variants when they have a low association with red hair
colour phenotype (RHC) and ‘R’ variants when they are highly
associated with RHC.18–20 Interestingly, R variants have been
associated with fairer skin phenotypes in women.21 Finally,
inherited MC1R variants increase the risk of developing a pri-
mary melanoma,22 yet appear to provide a survival advantage
to these individuals.23–25
We hypothesized that inherited MC1R variants could play a
differential role in survival in women and men.
Materials and methods
Cohort description
We used a cohort study design to analyse the prognostic value
of germline MC1R status depending on sex in patients with
melanoma. The cohort included 1341 consecutive patients
with melanoma who were prospectively followed-up in the
Melanoma Unit of Hospital Clinic of Barcelona, between Jan-
uary 1996 and April 2018. All patients gave their written
informed consent according to the Declaration of Helsinki,
and the study was approved by the Research Ethics Committee
of the Hospital Clinic of Barcelona (HCB/2015/0298 and
HCB/2015/1032).
Clinical and phenotypic data from the patients and mela-
noma characteristics were collected in the Melanoma Unit
database. For this study we extracted the basal demographic
characteristics of the patients, clinical and pathological mela-
noma features, and survival outcome.
As inclusion criteria, only patients with a histopathological
diagnosis of an invasive primary melanoma were considered
for the study. For patients with multiple melanomas, the most
invasive melanoma tumour by Breslow thickness was
included, as it is the one that drives the prognosis.
Sentinel lymph node biopsy and follow-up protocols were
carried out according to the institution’s guidelines.26,27 Over-
all survival (OS) time was calculated from the date of diagno-
sis of the primary melanoma to the date of death by any
cause or last follow-up visit. Melanoma-specific survival (MSS)
was calculated from the time of diagnosis of the primary mel-
anoma to the time of death by melanoma or the last follow-
up visit.
Our study was performed at a well-known referral centre
for advanced cases of melanoma, but bias may exist as it was
a single-centre study.
MC1R molecular screening
Genomic DNA was extracted from peripheral blood lympho-
cytes or saliva by standard methods. The whole coding region
of MC1R was sequenced as reported elsewhere.28
Nonsynonymous MC1R variants were classified as RHC (‘R’)
or non-RHC (‘r’) according to previously reported crite-
ria.20,23,28 Therefore, the p.D84E, p.R142H, p.R151C,
p.I155T, p.R160W and p.D294H MC1R variants were classified
as ‘R’, while all the other nonsynonymous MC1R variants were
classified as ‘r’. Synonymous variants were considered as wild-
type (WT) MC1R alleles (‘w’). According to this classification
we determined the following genotypes: R/R, R/r, R/w, r/r,
r/w, w/w.
Statistical analyses
Pearson’s v2-test, trend test for ordinal variables and the
Kruskal–Wallis rank sum test were used to compare categori-
cal, ordinal and continuous variables, respectively. Survival
curves based on Kaplan–Meier methods were used to calculate
survival outcomes and the log-rank test was used for curve
comparison.
We considered OS and MSS as the main variables. In order
to better manage possible statistical multiplicity when consid-
ering two primary variables (OS and MSS), P-values were con-
sidered statistically significant if P ≤ 0025, following
Bonferroni correction. If the described model produced proba-
bility values that reached significance, the following hierarchi-
cal stepwise process to reject the null hypotheses was
followed: the interaction effect with sex was evaluated and, if
this was significant at P < 010 (the usual cut-off for interac-
tion effects), the analysis was stratified by sex.29,30
Furthermore, in the stratified analysis, univariate and multi-
variate Cox logistic regression analysis were performed to
assess the influence of germline MC1R status in OS and MSS
depending on sex, and to estimate the hazard ratio (HR) for
each of the survival outcomes.
Statistical analyses were performed using the computing
environment R and RStudio.31,32
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Results
A total of 3999 patients with a histopathological diagnosis of
an invasive primary melanoma were identified. However, after
applying the inclusion and exclusion criteria, 2658 patients
were excluded, leaving 1341 eligible for inclusion (Fig. 1).
Total person-months were 105 775 with an incidence rate of
relapse of 272 cases per 1000 person-months. Median follow-
up time was 635 months (interquartile range 315–1159).
The demographic, clinical and genetic characteristics of all
included individuals are summarized in Table 1, and the clini-
copathological characteristics of all tumours are given in
Table 2. The average age of onset was 522 years in women and
567 years in men, and the mean Breslow thickness was 21 mm
and 25 mm, respectively. Phenotypic characteristics showed a
predominance of white skin, phototypes II and III, brown eyes
and brown hair. Women had thinner tumours, which were less
often ulcerated than those in men. Women presented more
often with superficial spreading melanomas and tumours on the
lower extremities. Men presented more often with nodular mel-
anomas and tumours on the trunk.
Considering that Breslow thickness and ulceration are two
of the main prognostic factors in melanoma, we evaluated
the association of MC1R genotype with these variables in our
cohort. We saw no significant differences between MC1R WT
individuals and MC1R variant carriers regarding Breslow index
(P = 0908). Similarly, no significant differences were
detected between MC1R WT and MC1R variant carriers when
stratified by ulceration (P = 0309) (Table S1; see Supporting
Information). Interestingly, the analysis was not statistically
significant when stratified for female sex (Breslow index P =
0895; ulceration P = 0925).
Kaplan–Meier curves showed that men had lower OS rates
than women (P < 0001; Fig. 2). This worse prognosis in
men was further confirmed in the analysis using the multivari-
ate Cox logistic regression model [HR 148, 95% confidence
interval (CI) 115–191; P = 0002].
Analysis stratified by sex and MC1R genotype
Kaplan–Meier curves were modelled for patients with MC1R
status. We did not detect statistically significant differences in
Patients with invasive melanoma
n= 3999
Excluded from the study: 
- n= 2549  No MC1R genotype
- n= 74      Diagnosis before 1996
- n= 35      No follow-up data


















Fig 1. Flowchart of the study cohort.
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OS between MC1R WT patients and carriers of any MC1R vari-
ant (P = 024; Fig. 3). Multivariate Cox regression analysis
adjusted by sex, age, Breslow index and ulceration showed
that MC1R genotype was not associated with better prognosis
in this cohort (HR 088, 95% CI 068–114; P = 0349).
We subsequently analysed the influence of sex on the effect
of MC1R variants in survival. Kaplan–Meier curves showed that
women with inherited MC1R variants had a better melanoma
prognosis than those with MC1R WT (P < 0007). In contrast,
the protective effect of inherited MC1R variants was not found
in men (P = 035; Fig. 3).
Subsequently, we evaluated the interaction effect of sex and
MC1R status for OS (P-value for interaction 0004) and for
MSS (P-value for interaction 0052), which were in both cases
statistically significant at alpha (P < 010), the usual measure
of statistical significance for interaction effect. Consequently,
Table 1 Demographic, clinical and genetic characteristics of patients included at baseline
Women (n = 697) Men (n = 644) Total (n = 1341) P-value
Mean  SD age of onset (y) 5222  1812 5668  1658 5437  1753 < 0001
Eye colour < 0001
Brown 355 (565) 335 (586) 690 (575)
Green 160 (255) 81 (142) 241 (201)
Blue 98 (156) 138 (241) 236 (197)
Black 13 (21) 11 (19) 24 (20)
Other 2 (03) 7 (12) 9 (08)
Missing 69 72 141
Hair colour < 0001
Brown 419 (669) 328 (575) 747 (625)
Black 29 (46) 64 (112) 93 (78)
Blonde 138 (220) 150 (263) 288 (241)
Red 40 (64) 28 (49) 68 (57)
Missing 71 74 145
Ethnicity 0620
White 629 (995) 574 (993) 1203 (994)
Latin 1 (02) 2 (03) 3 (02)
Asian 0 (00) 1 (02) 1 (01)
Black 0 (00) 0 (00) 0 (00)
Other 2 (03) 1 (02) 3 (02)
Missing 65 66 131
Phototype 0760
I 42 (66) 40 (68) 82 (67)
II 328 (513) 301 (515) 629 (514)
III 228 (357) 210 (359) 438 (358)
IV 40 (63) 33 (56) 73 (60)
V 1 (02) 1 (02) 2 (02)
Missing 58 59 117
Naevus count 0919
0–50 307 (540) 282 (536) 589 (538)
51–100 149 (262) 143 (272) 292 (267)
≥ 101 113 (199) 101 (192) 214 (195)
Missing 128 118 246
Number of melanomas 0036
Single 549 (788) 476 (739) 1025 (764)
Multiple 148 (212) 168 (261) 316 (236)
MC1R status 0488
Wild-type 215 (308) 210 (326) 425 (317)
Variants 482 (692) 434 (674) 916 (683)
MC1R genotype 0245
RR 34 (49) 31 (48) 65 (48)
Rr 80 (115) 51 (79) 131 (98)
Rw 116 (166) 121 (188) 237 (177)
rr 58 (83) 44 (68) 102 (76)
rw 194 (278) 187 (290) 381 (284)
ww 215 (308) 210 (326) 425 (317)
Data are n (%) unless otherwise indicated.
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we observed that the survival benefit derived from the MC1R
mutational status depends on the sex of the patients.
Univariate Cox logistic regression analysis of OS and MSS in
women showed that later age at onset, thicker tumours, high
mitotic index and tumour ulceration were associated with a
worse prognosis. By contrast, total naevus count > 50 and the
presence of inherited MC1R variants were protective.
Multivariate Cox logistic regression analysis including 630
women confirmed that the presence of inherited MC1R variants
was a protective factor for OS (HR 057, 95% CI 038–085; P
= 0006) and MSS (HR 049, 95% CI 029–081; P = 0005)
(Table 3). After adjustment for other baseline characteristics
(mitotic index, histological subtype and body site of the pri-
mary melanoma) the presence of any MC1R variation
Table 2 Clinicopathological characteristics of the included tumours
Women (n = 697) Men (n = 644) Total (n = 1341) P-value
Mean  SD Breslow index 210  327 247  281 228  306 < 0001
Ulceration < 0001
Absent 508 (806) 437 (722) 945 (765)
Present 122 (194) 168 (278) 290 (235)
Missing 67 39 106
Mean  SD mitotic index 218  395 253  459 235  428 0122
Missing 133 106 239
Location < 0001
Trunk 248 (382) 330 (541) 578 (459)
Lower limbs 184 (283) 78 (128) 262 (208)
Head and neck 69 (106) 95 (156) 164 (130)
Upper limbs 78 (120) 54 (89) 132 (105)
Acral 50 (77) 48 (79) 98 (78)
Mucosa 18 (28) 5 (08) 23 (18)
Other 3 (05) 0 (00) 3 (02)
Missing 47 34 81
Histological subtype 0003
Superficial spreading 459 (668) 397 (625) 856 (648)
Nodular 99 (144) 105 (165) 204 (154)
Acral lentiginous 33 (48) 45 (71) 78 (59)
Lentiginous malignant 27 (39) 46 (72) 73 (55)
Other 69 (100) 42 (66) 111 (84)
Missing 10 9 19
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Fig 2. Overall survival by sex.
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consistently showed a sizeable and statistical significance in
HR estimation for OS and MSS.
Similarly, univariate Cox logistic regression analysis in men
showed that later age at onset, thicker tumours, the presence
of ulceration and a high mitotic index were mortal risk fac-
tors, and a naevus total count > 50 was a protective factor.
Contrary to women, the presence of inherited MC1R variants
was not associated with improved survival in men. Multivari-
ate Cox logistic regression analysis including 605 men
showed no effects on OS (HR 126, 95% CI 089–179; P =
0185) or MSS (HR 109, 95% CI 071–167; P = 0685)
(Table 4).
Discussion
The significance of sex difference on melanoma prognosis is
well known. Better MSS in women has been attributed to both
lifestyle and biological factors. Women perform self-examina-
tion or tend to contact dermatologists for screening more
often than men, allowing an earlier diagnosis of melanoma in
women.33 Moreover, the survival prognosis is higher in
women than in men throughout childbearing age, except dur-
ing pregnancy. However, this survival benefit is not main-
tained after menopause. This suggests the importance of
hormonal signalling in melanoma development.34–36
A BioGenoMEL collaborative study suggested that the pres-
ence of any inherited MC1R variants was associated with
improved melanoma survival, adjusting for age and sex (HR
082, 95% CI 066–102; P = 008).23 The result only reached
statistical significance with the addition of the Leeds cohort
data (HR 077, 95% CI 064–093; P = 0005).23 Taylor et al.
also suggested that the presence of MC1R variants is associated
with better MSS (but not OS) in individuals with a first inci-
dent primary melanoma.25 These analyses did not stratify by
sex and, consequently, this putative protective effect in
women was not evaluated.
In our study we identified that inherited MC1R variants are



































































Fig 3. Overall survival by MC1R status depending on sex.
© 2019 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2020) 182, pp138–146
MC1R variants are associated with better survival in women, F.E. Lira et al. 143
Additionally, we did not observe more severe pathological
tumour characteristics in women with MC1R variants. There-
fore, our study indicates, for the first time, that the presence
of inherited MC1R variants may be an independent protective
factor in the survival of female patients with melanoma.
Although the sex-related biological mechanisms that underlie
this finding are unknown, we hypothesize that the regulation
of oxidative stress could offer a partial explanation. In melano-
cytes, the loss of melanocortin 1 receptor (MC1R) function
reduces DNA repair capacity and decreases antioxidant
response,37 causing genomic instability and increasing oxida-
tive stress.38 This may lead melanocytes to undergo malignant
transformation. Interestingly, oestrogen (the primary female
sex hormone) induces the generation of reactive oxidative spe-
cies (ROS).39 This fact is consistent with the higher incidence
of melanoma in adult premenopausal women.40 The effect of
ROS on malignant cell transformation is dose dependent.
While certain levels of ROS promote malignant transforma-
tion, excessively high ROS levels cause detrimental oxidative
stress that can lead to cell death.41 Therefore, we suggest that
in women melanocytes harbouring MC1R variants could cause
excessive oxidative damage that is detrimental to melanoma
progression.
Previous studies have indicated that inherited MC1R variants
contribute differently to pigmentation phenotype in men and
women. Moreover, women carrying RHC MC1R variants tended
to exhibit significantly fairer phototypes than men with the
same MC1R genotypes.42 Differences between the sexes accord-
ing to MC1R status do not only affect pigmentation phenotype.
A recently published study has shown that the risk of developing
melanoma associated with inherited MC1R variants is much
higher in women than in men.43 In the same line, several









[HR (95% CI, P-value)]b
Inherited MC1R
variants (yes)
057 (039–083, 0003) 057 (038–085, 0006) 053 (034–085, 0008) 049 (029–081, 0005)
Age (continuous) 106 (105–108, < 0001) 106 (105–108, < 0001) 104 (103–106, < 0001) 104 (102–105, < 0001)
Breslow index
(continuous)
106 (104–108, < 0001) 104 (101–106, 0006) 106 (104–108, < 0001) 103 (100–107, 0027)
Ulceration (present) 371 (248–556, < 0001) 196 (127–301, 0002) 483 (292–800, < 0001) 302 (176–518, < 0001)
Mitotic index
(continuous)
109 (106–113, < 0001) – 112 (108–116, < 0001) –
Naevus total
count (< 50)
– – – –
51–100 052 (029–092, 0026) – 073 (038–139, 0335) –
≥ 101 041 (021–081, 0010) – 047 (021–107, 0072) –
HR, hazard ratio; CI, confidence interval. aMultivariable analysis based on 630 women and 101 events (C-index = 0784); bMultivariable
analysis based on 630 women and 63 events (C-index = 0777)
Table 4 Univariate and multivariate Cox regression analysis of overall survival (OS) and melanoma-specific survival (MSS) in men
OS MSS
Univariable
[HR (95% CI, P-value)]
Multivariable
[HR (95% CI, P-value)]a
Univariable
[HR (95% CI, P-value)]
Multivariable
[HR (95% CI, P-value)]b
Inherited MC1R
variants (yes)
117 (084–163, 0347) 126 (089–179, 0185) 098 (065–147, 0917) 109 (071–167, 0685)
Age (continuous) 105 (104–106, < 0001) 104 (103–105, < 0001) 102 (101–103, 0001) 102 (100–103, 0011)
Breslow index
(continuous)
118 (114–122, < 0001) 115 (110–120, < 0001) 121 (117–125, < 0001) 117 (112–123, < 0001)
Ulceration (present) 275 (202–375, < 0001) 141 (097–206, 0074) 355 (240–525, < 0001) 180 (113–288, 0013)
Mitotic index
(continuous)
106 (103–108, < 0001) – 108 (105–111, < 0001) –
Naevus total
count (< 50)
– – – –
51–100 047 (028–077, 0003) – 049 (026–093, 0030) –
≥ 101 065 (040–106, 0086) – 059 (030–115, 0119) –
HR, hazard ratio; CI, confidence interval. aMultivariable analysis based on 605 men and 165 events (C-index = 0758). bMultivariable analysis
based on 605 men and 103 events (C-index = 0758)
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studies have identified a sex-differential effect of MC1R on anal-
gesic response.21,44 Specifically, women with two inherited
MC1R variants show greater analgesia than men.44 Taken
together, these findings highlight the fact that MC1R is a pleio-
tropic protein involved in the regulation of different biological
processes and show that some of these MC1R effects are sex
dependent.
In conclusion, our results show that the presence of inher-
ited MC1R variants improves survival in women with mela-
noma. This could explain some of the prognostic differences
between men and women. Future prospective studies should
take into account sex differences in survival and could help to
explain how the inherited MC1R variants may play a role in
survival. This could imply an improvement in personalized
melanoma follow-up.
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